{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:17:03Z","timestamp":1785521823252,"version":"3.56.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":75,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-10260-6","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:37:11Z","timestamp":1778733431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing Azeliragon as a novel antibacterial agent against methicillin-resistant Staphylococcus aureus via combined membrane phospholipids and cell wall targeting"],"prefix":"10.1038","volume":"9","author":[{"given":"Junhua","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9849-4229","authenticated-orcid":false,"given":"Bao","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-9860","authenticated-orcid":false,"given":"Bing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8765-9339","authenticated-orcid":false,"given":"TieYing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9934-2056","authenticated-orcid":false,"given":"Zewen","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"10260_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/ph18010081","volume":"18","author":"M Michalik","year":"2025","unstructured":"Michalik, M., Podbielska-Kubera, A. & Dmowska-Koroblewska, A. Antibiotic resistance of Staphylococcus aureus strains-searching for new antimicrobial agents-review. Pharmaceuticals 18, 81 (2025).","journal-title":"Pharmaceuticals"},{"key":"10260_CR2","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/s42003-024-07216-z","volume":"7","author":"K Zhang","year":"2024","unstructured":"Zhang, K. et al. An amphipathic peptide combats multidrug-resistant Staphylococcus aureus and biofilms. Commun. Biol. 7, 1582 (2024).","journal-title":"Commun. Biol."},{"key":"10260_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-88743-5","volume":"15","author":"R Mohammed","year":"2025","unstructured":"Mohammed, R., Nader, S. M., Hamza, D. A. & Sabry, M. A. Public health implications of multidrugresistant and methicillinresistant Staphylococcus aureus in retail oysters. Sci. Rep. 15, 4496 (2025).","journal-title":"Sci. Rep."},{"key":"10260_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cancers17010017","volume":"17","author":"K Alka","year":"2024","unstructured":"Alka, K. et al. The RAGE inhibitor TTP488 (Azeliragon) demonstrates anti-tumor activity and enhances the efficacy of radiation therapy in pancreatic cancer cell lines. Cancers 17, 17 (2024).","journal-title":"Cancers"},{"key":"10260_CR5","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1038\/s41564-024-01769-9","volume":"9","author":"A Urso","year":"2024","unstructured":"Urso, A. et al. Staphylococcus aureus adapts to exploit collagen-derived proline during chronic infection. Nat. Microbiol. 9, 2506\u20132521 (2024).","journal-title":"Nat. Microbiol."},{"key":"10260_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84307-1","volume":"15","author":"C de Oliveira Whitaker","year":"2025","unstructured":"de Oliveira Whitaker, C. et al. Clonal shift and impact of azithromycin use on antimicrobial resistance of Staphylococcus aureus isolated from bloodstream infection during the COVID-19 pandemic. Sci. Rep. 15, 597 (2025).","journal-title":"Sci. Rep."},{"key":"10260_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86334-y","volume":"15","author":"SA Maan","year":"2025","unstructured":"Maan, S. A., Faiesal, A. A., Gamar, G. M. & El Dougdoug, N. K. Efficacy of bacteriophages with Aloe vera extract in formulated cosmetics to combat multidrug-resistant bacteria in skin diseases. Sci. Rep. 15, 4335 (2025).","journal-title":"Sci. Rep."},{"key":"10260_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12929-024-01109-3","volume":"32","author":"M Sultan","year":"2025","unstructured":"Sultan, M. et al. Targeting the G-quadruplex as a novel strategy for developing antibiotics against hypervirulent drug-resistant Staphylococcus aureus. J. Biomed. Sci. 32, 15 (2025).","journal-title":"J. Biomed. Sci."},{"key":"10260_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12887-025-05433-x","volume":"25","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Analysis of antimicrobial resistance and clinical features of Staphylococcus aureus-infected bone and joint infections in children. BMC Pediatr. 25, 83 (2025).","journal-title":"BMC Pediatr."},{"key":"10260_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.104915","volume":"156","author":"WT Liu","year":"2021","unstructured":"Liu, W. T. et al. Emerging resistance mechanisms for 4 types of common anti-MRSA antibiotics in Staphylococcus aureus: a comprehensive review. Micro. Pathog. 156, 104915 (2021).","journal-title":"Micro. Pathog."},{"key":"10260_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e41537","volume":"11","author":"N Jomehzadeh","year":"2025","unstructured":"Jomehzadeh, N. & Emrani, S. S. Assessment of biofilm formation, antibiotic resistance patterns, and the prevalence of adhesion-related genes in clinical Staphylococcus aureus isolates. Heliyon 11, e41537 (2025).","journal-title":"Heliyon"},{"key":"10260_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s44259-024-00046-3","volume":"2","author":"HY Liu","year":"2024","unstructured":"Liu, H. Y., Prentice, E. L. & Webber, M. A. Mechanisms of antimicrobial resistance in biofilms. NPJ Antimicrob. Resist 2, 27 (2024).","journal-title":"NPJ Antimicrob. Resist"},{"key":"10260_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41564-019-0357-1","volume":"4","author":"MA Farha","year":"2019","unstructured":"Farha, M. A. & Brown, E. D. Drug repurposing for antimicrobial discovery. Nat. Microbiol. 4, 565\u2013577 (2019).","journal-title":"Nat. Microbiol."},{"key":"10260_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10260_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2020.02.056","volume":"181","author":"K Lewis","year":"2020","unstructured":"Lewis, K. The science of antibiotic discovery. Cell 181, 29\u201345 (2020).","journal-title":"Cell"},{"key":"10260_CR16","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1093\/jac\/dkv163","volume":"70","author":"L Aguinagalde","year":"2015","unstructured":"Aguinagalde, L. et al. Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections. J. Antimicrob. Chemother. 70, 2608\u20132617 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"10260_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.790","volume":"12","author":"A Weiss","year":"2022","unstructured":"Weiss, A. et al. Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial. Clin. Transl. Med. 12, e790 (2022).","journal-title":"Clin. Transl. Med."},{"key":"10260_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2018.18","volume":"5","author":"AH Burstein","year":"2018","unstructured":"Burstein, A. H. et al. Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 5, 149\u2013154 (2018).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10260_CR19","doi-asserted-by":"publisher","first-page":"viii91","DOI":"10.1093\/neuonc\/noae165.0359","volume":"26","author":"J Huang","year":"2024","unstructured":"Huang, J. et al. CTIM-26. Phase II study of Azeliragon in combination with radiation therapy in newly diagnosed patients with MGMT-unmethylated glioblastoma. Neuro Oncol. 26, viii91\u2013viii91 (2024).","journal-title":"Neuro Oncol."},{"key":"10260_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109165","volume":"245","author":"AA Joshi","year":"2022","unstructured":"Joshi, A. A. et al. RAGE antagonism with azeliragon improves xenograft rejection by T cells in humanized mice. Clin. Immunol. 245, 109165 (2022).","journal-title":"Clin. Immunol."},{"key":"10260_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/gutjnl-2024-332193","volume":"74","author":"Q Zhou","year":"2025","unstructured":"Zhou, Q. et al. Microbiota-induced S100A11-RAGE axis underlies immune evasion in right-sided colon adenomas and is a therapeutic target to boost anti-PD1 efficacy. Gut. 74, 214\u2013228 (2025).","journal-title":"Gut."},{"key":"10260_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3390\/biomedicines11041131","volume":"11","author":"VP Reddy","year":"2023","unstructured":"Reddy, V. P., Aryal, P. & Soni, P. RAGE inhibitors in neurodegenerative diseases. Biomedicines 11, 1131 (2023).","journal-title":"Biomedicines"},{"key":"10260_CR23","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1007\/s11010-024-05132-8","volume":"480","author":"V Rai","year":"2025","unstructured":"Rai, V., Deepu, V. & Agrawal, D. K. Targeting RAGE-signaling pathways in the repair of rotator-cuff injury. Mol. Cell Biochem. 480, 2539\u20132554 (2025).","journal-title":"Mol. Cell Biochem."},{"key":"10260_CR24","doi-asserted-by":"publisher","first-page":"TPS4212","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4212","volume":"42","author":"AE Hendifar","year":"2024","unstructured":"Hendifar, A. E. et al. A phase I\/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer. J. Clin. Oncol. 42, TPS4212\u2013TPS4212 (2024).","journal-title":"J. Clin. Oncol."},{"key":"10260_CR25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1517\/14728222.2014.925881","volume":"18","author":"F Baquero","year":"2014","unstructured":"Baquero, F., Coque, T. M. & Cant\u00f3n, R. Counteracting antibiotic resistance: breaking barriers among antibacterial strategies. Expert Opin. Ther. Targets 18, 851\u2013861 (2014).","journal-title":"Expert Opin. Ther. Targets"},{"key":"10260_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23659-y","volume":"12","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Multi-target mode of action of silver against Staphylococcus aureus endows it with capability to combat antibiotic resistance. Nat. Commun. 12, 3331 (2021).","journal-title":"Nat. Commun."},{"key":"10260_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.00425-25","volume":"10","author":"P She","year":"2025","unstructured":"She, P. et al. Repurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistant Enterococcus membranes. mSystems 10, e0042525 (2025).","journal-title":"mSystems"},{"key":"10260_CR28","doi-asserted-by":"publisher","first-page":"21984","DOI":"10.1073\/pnas.0910040106","volume":"106","author":"B Lomenick","year":"2009","unstructured":"Lomenick, B. et al. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci. USA. 106, 21984\u201321989 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10260_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41586-023-05750-0","volume":"615","author":"KR Hummels","year":"2023","unstructured":"Hummels, K. R. et al. Coordination of bacterial cell wall and outer membrane biosynthesis. Nature 615, 300\u2013304 (2023).","journal-title":"Nature"},{"key":"10260_CR30","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S0969-2126(96)00153-0","volume":"4","author":"T Skarzynski","year":"1996","unstructured":"Skarzynski, T. et al. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure 4, 1465\u20131474 (1996).","journal-title":"Structure"},{"key":"10260_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00253-011-3512-z","volume":"92","author":"A Gautam","year":"2011","unstructured":"Gautam, A., Rishi, P. & Tewari, R. UDP-N-acetylglucosamine enolpyruvyl transferase as a potential target for antibacterial chemotherapy: recent developments. Appl. Microbiol. Biotechnol. 92, 211\u2013225 (2011).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10260_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00564-9","volume":"9","author":"M Magna","year":"2023","unstructured":"Magna, M. et al. RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer. npj Breast Cancer 9, 59 (2023).","journal-title":"npj Breast Cancer"},{"key":"10260_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1035574","volume":"9","author":"AH Nguyen","year":"2022","unstructured":"Nguyen, A. H., Hood, K. S., Mileykovskaya, E., Miller, W. R. & Tran, T. T. Bacterial cell membranes and their role in daptomycin resistance: a review. Front. Mol. Biosci. 9, 1035574 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"10260_CR34","doi-asserted-by":"publisher","unstructured":"Miller, W. R., Bayer, A. S. & Arias, C. A. Mechanism of action and resistance to daptomycin in Staphylococcus aureus and Enterococci. Cold Spring Harb. Perspect. Med. 6, https:\/\/doi.org\/10.1101\/cshperspect.a026997 (2016).","DOI":"10.1101\/cshperspect.a026997"},{"key":"10260_CR35","doi-asserted-by":"publisher","first-page":"10646","DOI":"10.1021\/bi00201a011","volume":"33","author":"JL Marquardt","year":"1994","unstructured":"Marquardt, J. L. et al. Kinetics, stoichiometry, and identification of the reactive thiolate in the inactivation of UDP-GlcNAc enolpyruvoyl transferase by the antibiotic fosfomycin. Biochemistry 33, 10646\u201310651 (1994).","journal-title":"Biochemistry"},{"key":"10260_CR36","doi-asserted-by":"publisher","unstructured":"Silver, L. L. Fosfomycin: mechanism and resistance. Cold Spring Harb. Perspect. Med. 7, https:\/\/doi.org\/10.1101\/cshperspect.a025262 (2017).","DOI":"10.1101\/cshperspect.a025262"},{"key":"10260_CR37","unstructured":"Engel, M., Fathalla, R. K. & Ducho, C. in Annual Reports in Medicinal Chemistry Vol. 60 (ed C. Ducho) 87\u2013105 (Academic Press, 2023)."},{"key":"10260_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jgar.2022.05.026","volume":"30","author":"L Xin","year":"2022","unstructured":"Xin, L. et al. Asp50Glu mutation in MurA results in fosfomycin resistance in Enterococcus faecium. J. Glob. Antimicrob. Resist 30, 50\u201355 (2022).","journal-title":"J. Glob. Antimicrob. Resist"},{"key":"10260_CR39","doi-asserted-by":"publisher","first-page":"11715","DOI":"10.1021\/bi901524q","volume":"48","author":"SG Jackson","year":"2009","unstructured":"Jackson, S. G., Zhang, F., Chindemi, P., Junop, M. S. & Berti, P. J. Evidence of kinetic control of ligand binding and staged product release in MurA (enolpyruvyl UDP-GlcNAc synthase)-catalyzed reactions. Biochemistry 48, 11715\u201311723 (2009).","journal-title":"Biochemistry"},{"key":"10260_CR40","doi-asserted-by":"publisher","first-page":"e3000819","DOI":"10.1371\/journal.pbio.3000819","volume":"18","author":"A Nyerges","year":"2020","unstructured":"Nyerges, A. et al. Rational design of balanced dual-targeting antibiotics with limited resistance. PLoS Biol. 18, e3000819 (2020).","journal-title":"PLoS Biol."},{"key":"10260_CR41","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1128\/JB.02607-14","volume":"197","author":"H Alnaseri","year":"2015","unstructured":"Alnaseri, H. et al. Inducible expression of a resistance-nodulation-division-type efflux pump in Staphylococcus aureus provides resistance to linoleic and arachidonic acids. J. Bacteriol. 197, 1893\u20131905 (2015).","journal-title":"J. Bacteriol."},{"key":"10260_CR42","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3389\/fmicb.2019.01157","volume":"10","author":"MT Nguyen","year":"2019","unstructured":"Nguyen, M. T. et al. Inactivation of farR causes high rhodomyrtone resistance and increased pathogenicity in Staphylococcus aureus. Front Microbiol 10, 1157 (2019).","journal-title":"Front Microbiol"},{"key":"10260_CR43","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/microorganisms10071385","volume":"10","author":"J Dawan","year":"2022","unstructured":"Dawan, J. & Ahn, J. Bacterial stress responses as potential targets in overcoming antibiotic resistance. Microorganisms 10, 1385 (2022).","journal-title":"Microorganisms"},{"key":"10260_CR44","unstructured":"Therapeutics, V. vTv Therapeutics announces topline results from the first STEADFAST Phase 3 study evaluating azeliragon in people with mild Alzheimer's disease. vTv Therapeutics press release https:\/\/ir.vtvtherapeutics.com\/news-releases\/news-release-details\/vtv-therapeutics-announces-topline-results-first-steadfast-phase (2018)."},{"key":"10260_CR45","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","volume":"83","author":"A Bierhaus","year":"2005","unstructured":"Bierhaus, A. et al. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83, 876\u2013886 (2005).","journal-title":"J. Mol. Med."},{"key":"10260_CR46","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1021\/acsomega.2c06569","volume":"8","author":"Y Tang","year":"2023","unstructured":"Tang, Y. et al. Antibacterial and antibiofilm activities of sertindole and its antibacterial mechanism against Staphylococcus aureus. ACS Omega 8, 5415\u20135425 (2023).","journal-title":"ACS Omega"},{"key":"10260_CR47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12866-024-03377-3","volume":"24","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Antibacterial activity and mechanisms of D-3263 against Staphylococcus aureus. BMC Microbiol. 24, 224 (2024).","journal-title":"BMC Microbiol."},{"key":"10260_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103731","volume":"25","author":"J Zheng","year":"2022","unstructured":"Zheng, J. et al. Loratadine inhibits Staphylococcus aureus virulence and biofilm formation. iScience 25, 103731 (2022).","journal-title":"iScience"},{"key":"10260_CR49","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1021\/acsinfecdis.4c01020","volume":"11","author":"X Liu","year":"2025","unstructured":"Liu, X. et al. Derazantinib inhibits the planktonic growth and biofilm formation of Staphylococcus aureus by binding membrane phospholipids and disrupting the cell membrane. ACS Infect. Dis. 11, 1473\u20131485 (2025).","journal-title":"ACS Infect. Dis."},{"key":"10260_CR50","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12866-025-04163-5","volume":"25","author":"X Huang","year":"2025","unstructured":"Huang, X. et al. Repurposing Etalocib suppresses multidrug-resistant Staphylococcus aureus by disrupting the bacterial membrane. BMC Microbiol. 25, 472 (2025).","journal-title":"BMC Microbiol."},{"key":"10260_CR51","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1021\/acsinfecdis.3c00188","volume":"9","author":"Z Wen","year":"2023","unstructured":"Wen, Z. et al. In vitro, in vivo, and in silico activities of ginkgolic acid C15:1 against Streptococcus agalactiae clinical isolates. ACS Infect. Dis. 9, 1867\u20131877 (2023).","journal-title":"ACS Infect. Dis."},{"key":"10260_CR52","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1021\/acs.biochem.0c00502","volume":"59","author":"T Zhang","year":"2020","unstructured":"Zhang, T., Hansen, K., Politis, A. & Muller, M. M. An unusually rapid protein backbone modification stabilizes the essential bacterial enzyme MurA. Biochemistry 59, 3683\u20133695 (2020).","journal-title":"Biochemistry"},{"key":"10260_CR53","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12866-022-02535-9","volume":"22","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Antibacterial activities and action mode of anti-hyperlipidemic lomitapide against Staphylococcus aureus. BMC Microbiol. 22, 114 (2022).","journal-title":"BMC Microbiol."},{"key":"10260_CR54","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00991-21","volume":"10","author":"Z Wen","year":"2022","unstructured":"Wen, Z. et al. The mechanism of action of ginkgolic acid (15:1) against Gram-positive bacteria involves cross talk with iron homeostasis. Microbiol. Spectr. 10, e0099121 (2022).","journal-title":"Microbiol. Spectr."},{"key":"10260_CR55","doi-asserted-by":"publisher","unstructured":"Huang, X. et al. Repurposing GSK2018682 confers dual antibacterial and antibiofilm activity against Staphylococcus aureus. ACS Infect. Dis. https:\/\/doi.org\/10.1021\/acsinfecdis.5c00780 (2026)","DOI":"10.1021\/acsinfecdis.5c00780"},{"key":"10260_CR56","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1016\/j.apsb.2024.03.017","volume":"14","author":"J Hu","year":"2024","unstructured":"Hu, J. et al. Allosterically activating SHP2 by oleanolic acid inhibits STAT3-Th17 axis for ameliorating colitis. Acta Pharm. Sin. B 14, 2598\u20132612 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"10260_CR57","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02451-21","volume":"10","author":"O Gordon","year":"2022","unstructured":"Gordon, O. et al. The novel oxazolidinone TBI-223 is effective in three preclinical mouse models of methicillin-resistant Staphylococcus aureus infection. Microbiol. Spectr. 10, e0245121 (2022).","journal-title":"Microbiol. Spectr."},{"key":"10260_CR58","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/nsmb830","volume":"11","author":"ST Hsu","year":"2004","unstructured":"Hsu, S. T. et al. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 11, 963\u2013967 (2004).","journal-title":"Nat. Struct. Mol. Biol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10260-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:07:12Z","timestamp":1785517632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10260"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10260-6","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1022"}}